At the clinical level in HNSCC, YAP and TAZ have been proposed as poor prognosis markers [24,91,92,93,94] and YAP activation has been associated with resistance to different anticancer therapies [95,96,97]. This evidence concerns the gene YAP1 and head and neck squamous cell carcinoma.